Total raised
—
Last: Seed 2020-02
Stage
Acquired
Founded
2017
Headcount
2
HQ
Yavne
Sector
Health Tech & Life Sciences
About
Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company extends its pipeline and uses tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells.
Funding history · 3 rounds · — total
2020-02
Seed
Undisclosed
2019-04
Seed
Undisclosed
2017-12
Seed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Immunorizon's primary focus in cancer therapy?
- Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy, utilizing tri-specific constructs with additional tumor-associated antigens.
- When was Immunorizon founded?
- Immunorizon was founded in December 2017.
- What was Immunorizon's former name?
- Immunorizon was formerly known as ExploreBio1.
- When and by whom was Immunorizon acquired?
- Immunorizon was acquired by Purple Biotech in February 2023 for $100,000,000.
- Which investors participated in Immunorizon's seed funding rounds?
- Immunorizon received seed funding from investors including M Ventures and ExploreBio.
- What is the employee count for Immunorizon?
- Immunorizon has 2 employees, falling into the 1-10 employee bucket.
- What is Immunorizon's current operational status?
- Immunorizon's current operational status is 'acquired', following its acquisition by Purple Biotech in February 2023.
- In which city is Immunorizon headquartered?
- Immunorizon is headquartered in Yavne, Israel.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Business model
B2B
Tags
cancer-therapyimmunologyoncologyantibodiesbiotechnology